ImmunityBio (IBRX) Executes $40M Equity Financing with Institutional Investors

Go back to ImmunityBio (IBRX) Executes $40M Equity Financing with Institutional Investors

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors

July 20, 2023 8:32 PM UTC

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors, providing for the issuance of common stock of... More